ABSTRACT. Long-chain acyl-CoA dehydrogenase (LCAD) deficiency is a disorder of mitochondria1 fatty acid oxidation that is characterized by hypoglycemia, muscle weakness, and hepato-and cardiomegaly. To characterize variant LCAD, we first carried out preliminary experiments using pure enzyme preparations. Despite the significant sequence similarity of LCAD to medium-chain acylCoA dehydrogenase, the antibody raised against rat LCAD was monospecific for human and rat LCAD and did not cross-react with either human or rat medium-chain acylCoA dehydrogenase. Immunoblot analysis of variant LCAD in cultured fibroblasts from nine patients with LCAD deficiency revealed a single LCAD band in all nine LCAD-deficient cell lines. Each variant LCAD was comparable in molecular size and quantity to normal LCAD, suggesting that the LCAD mutation in each of these cell lines is likely to be a point mutation that produces a stable variant LCAD. The uniform nature of variant LCAD suggests that only a single, or at most a few, prevalent point mutations may be found in the majority of LCAD-deficient patients. If this is the case, it should be possible to devise a molecular diagnostic method for LCAD deficiency. (Pediatr Res 30: [211][212][213][214][215] 1991) Abbreviations LCAD, long-chain acyl-CoA dehydrogenase MCAD, medium-chain acyl-CoA dehydrogenase SCAD, short-chain acyl-CoA dehydrogenase LCAD deficiency is an autosomal recessive disorder of fatty acid metabolism. It was first described in three infants in 1985 by Hale et al. (1). Subsequently, 1 1 additional patients have been identified (2). The main clinical features seen in these patients were severe hypoglycemia, skeletal muscle weakness, and hepatomegaly; cardiomegaly was a significant feature in eight patients. Six of them died in early infancy; however, the clinical manifestations in some other cases were much milder (1, 2), suggesting
' Present address: Kumamoto University Medical School, Department of Pediatrics, Kumamoto City 860, Japan. heterogeneity. Heterogeneity of LCAD deficiency was also suggested by a biochemical assay (3) . As in the case of MCAD deficiency (4) , some patients with LCAD deficiency abruptly died with few prodromal symptoms, mimicking sudden infant death syndrome (5) . No urinary metabolites are specific for this disease, making it difficult to establish the diagnosis. At present, the diagnosis of LCAD deficiency is made by the assay of LCAD activity in cells such as fibroblasts and leukocytes or in solid tissues; however, methods for the assay of LCAD and other acylCoA dehydrogenase activities are cumbersome and time-consuming.
As the first step in the molecular characterization of mutations of human LCAD that cause LCAD deficiency, we studied the variant LCAD protein in cultured fibroblasts from nine patients with LCAD deficiency using immunoblot analysis.
MATERIALS AND METHODS

Materials.
Purification of MCAD and LCAD from rat liver mitochondria and the preparation of the respective antibodies were previously reported by Ikeda et al. (6) . These antibodies also recognized the respective human enzymes as well (7) . Purification of human MCAD was reported by Finocchiaro et al. (8) . Tissue culture materials were obtained from GIBCO (Grand Island, NY) . Inactivated Staphylococcus aureus cells were from Bethesda Research Laboratories (Gaithersburg, MD) .
Source offibroblast cultures. Cell cultures were obtained from nine unrelated LCAD-deficient patients who have been reported previously (1, 2) . All patients were unrelated. The identification of the LCAD-deficient cells is as follows: YH 14 14, J-1; YH 14 18, A-1 ; and YH 1435, R-1, as reported in reference 1. The identification numbers of the six other LCAD-deficient cell lines are identical to those in the original report (2) , except that each number is preceded by the two letters CP. The deficiency of LCAD activity in these cells was confirmed using the electron transfer flavoprotein-dependent fluorometric assay. Clinically, YH 1414, YH1418, YH1435, CP2, CP3, and CP8 belong to the first type, which is characterized by early onset, high mortality, and cardiac involvement. CP9 and CPl 1 belong to the second type, which is acute and of early onset but presents no cardiac dysfunction or muscle weakness. C14 belongs to the third type, which is characterized by a late onset (2) . Normal cell cultures were obtained from the Human Genetic Mutant Cell Repository (Camden, NJ).
Cell culture and protein chemistry. Cell culture and extraction of cell proteins were canied out as previously described (9) . The protein concentration was determined by the method of Branford (10) using bovine gamma globulin as a standard.
Immunoabsorption of pure enzyme preparations and cell extracts with antibody. The indicated amount of pure enzyme preparations was dissolved in 100 pL of the extraction buffer, to which 0.1% BSA was added as a camer. The enzyme solution was mixed with 2-pL of the antibody against the enzyme to be removed and left at 4°C overnight. In the case of cell extracts, insoluble materials were first removed by centrifugation, and the supernatant was similarly treated with antibody. Fifty pL of 10% S. aureus suspension were then added, and allowed to react for 15 min at room temperature. The immune complex bound to S. aureus cells was removed by centrifugation. The supernatant was used for further analysis by SDS-PAGE.
SDS-PAGE and immunoblot analysis. SDS-PAGE was camed out on 10% polyacrylamide-gel slabs with a 5% stacking gel, using the discontinuous buffer system described by Laemmli (1 1). When pure enzyme was used as standard, 1 mg/mL of BSA was included in the standard solution to avoid the loss of antigen due to adsorption. After electrophoresis, gel was electroblotted onto a nitrocellulose (Schleicher and Schuell, Keene, NH) or Immobilon-P sheet (Millipore, Bedford, MA), according to the method described by Towbin et al. (12) . The blot was treated as described previously (I 3) , except that incubation with the specific antibodv was done for 1 h. The anti~enlantibodv com~lex was detected using the alkaline phosph~ask-conjug~ted goat antirabbit IgG system (Bio-Rad Laboratories, Richmond, CA).
RESULTS
Characterization of interactions of rat and human L C A D and
M C A D with homologous and heterologous antibodies raised against rat enzymes. We previously observed that, unlike other human acyl-CoA dehydrogenases, human LCAD was not immunoprecipitated as native protein by the antibody raised against its rat counterpart (7). Therefore, [35S]methionine-labeling/immunoprecipitation of human LCAD could not be performed. However, we subsequently found that immunoblotted human LCAD was strongly recognized by anti-rat LCAD antibody, possibly due to unfolding of the protein by SDS.
To characterize the immunoreactions of LCAD and MCAD, both human and rat, we first camed out three sets of preliminary experiments with the pertinent antibodies for the following reasons. First, although rat LCAD did not cross-react with anti-MCAD antibody nor did MCAD cross-react with anti-LCAD antibody as native proteins (6) , their cross-reactivity in the denatured state was unknown. Furthermore, the electrophoretic mobility of authentic human LCAD was unknown, inasmuch as human LCAD has never been purified. The electrophoretic mobilities of rat LCAD and MCAD were indistinguishable, but other acyl-CoA dehydrogenases can be readily distinguished from each other by slight but distinct differences in their electrophoretic mobility (6) .
In the first set of experiments, we camed out immunoabsorption experiments using the purified rat enzymes to test whether it is necessary to remove a small amount of contaminating enzyme that may be present in the purified LCAD or MCAD preparations and may interfere with the immunoreactions. These experiments served also to characterize the specificity of antibodies toward denatured acyl-CoA dehydrogenases. We first camed out preabsorption of pure rat MCAD by incubating it with anti-LCAD antibody or preimmune serum, followed by mixing with S. aureus cell suspension; in this system, the immune complex binds to Protein A in S . aureus cells and precipitates. The supernatant was electrophoresed and electroblotted, and the proteins detected using anti-MCAD antibody as probe. When the pure rat MCAD preparation2 was directly applied to the gel without preabsorption, MCAD above the amount of 10 ng was readily detectable (Fig. IA, lanes I and 2) . When 133 and 13.3 ng of pure rat MCAD were subjected to preabsorption with preimmune serum followed by electrophoresis and electroblot, a recognizable loss of MCAD occurred, but both bands were readily detectable (Fig. IA , lanes 3 and 5) . When the same amounts of the MCAD preparation were preabsorbed with anti-LCAD antibody, the amount of MCAD detected was comparable LCADrl Fig. 1 . Characterization of antibody by preabsorption and immunoblot analysis. Pure enzymes (400 or 40 ng) in 100 pL of buffer were preabsorbed with 2 pL of preimmune, anti-MCAD, or anti-LCAD antibody, followed by mixing with 50 pL of 10% S. aureus suspension and centrifugation. One third of each supernatant was subjected to immunoblot analysis as described in Materials and Methods. A, Immunodetection of purified rat MCAD using anti-MCAD antibody as a probe with and without preabsorption with anti-LCAD antibody. Lanes 1 and 2, 100 and 10 ng, respectively, of purified rat MCAD were directly applied as standard; lanes 3 and 4, 133 ng of rat MCAD after preabsorption with preimmune rabbit serum and anti-LCAD antibody, respectively; lanes 5 and 6, 13.3 ng of rat MCAD after preabsorption with preimmune rabbit serum and anti-LCAD antibody, respectively. The intense bands above the MCAD bands (lanes [3] [4] [5] [6] are the heavy chain of IgG derived from the preimmune serum or the antibodies used. The broad, faint bands seen in each lane are a result of BSA being used as a camer. B, Immunodetection of purified rat MCAD using anti-LCAD antibody as a probe after preabsorption with anti-LCAD antibody. This experiment was designed to test whether the rat MCAD preparation is cross-reactive to anti-LCAD antibody. Lanes I and 2, 100 and 10 ng, respectively, of purified rat LCAD were directly applied as an electrophoretic standard; lanes 3 and 4, 133 ng of purified rat MCAD after preabsorption with preimmune rabbit serum and anti-LCAD antibody, respectively; lanes 5 and 6, 13.3 ng of pure rat MCAD after preabsorption with preimmune rabbit serum and anti-LCAD antibody, respectively. C, Immunodetection of vurified rat LCAD, with and without vreabsomtion with anti-LCAD antibody, using anti-LCAD antibody as a probe. Lane 1, 15 ng of rat LCAD was directly applied as a standard; lanes 2 and 3, Despite their high purity, most of the rat and human MCAD preparations 133 and 13.3 ng, respectively, of rat LCAD after preabsorption with exhibited double bands when analyzed on SDS-PAGE (6, 8) . The double bands preimmune rabbit serum; lanes 4 and 5, 133 and 13.3 ng, respectively, can be immunoprecipitated by anti-rat MCAD antibody with equal deficiency, indicating their identity. The determination of the amino terminal sequence indiof pure rat LCAD after preabsorption with anti-MCAD antibody; lanes cated that the double band is due to a loss of several amino acid residues from the 6 and 7, 133 and 13.3 ng, respectively, of Pure rat LCAD after preabamino terminus in some of the MCAD molecules (6) . sorption with anti-LCAD antibody.
to that detected after absorption with preimmune serum (Fig.  1 A, lanes 4 and 6) , indicating that anti-LCAD antibody does not precipitate rat MCAD.
In the second experiment of this set, the same aliquots of the same MCAD preparation were analyzed by electrophoresis and electroblotted in the same manner as in the first experiment, but immunodetection of proteins was done using anti-LCAD antibody as a probe (Fig. IB) . In lanes I and 2, 100 and 10 ng, respectively, of the purified rat LCAD preparation was directly applied to SDS-PAGE as a standard without preabsorption. When the rat MCAD preparation was preabsorbed with either anti-LCAD antibody or preimmune serum and probed with anti-LCAD antibody, no band was detectable (Fig. lB, lanes 3-6) , indicating that rat MCAD, even at 133 ng, did not cross-react with anti-LCAD antibody. In the third experiment, the rat LCAD preparation was immunoblotted after preabsorption with preimmune serum (lanes 2 and 3) , anti-MCAD (lanes 4 and5) or anti-LCAD antibody (lanes 6 and 7), and probed with anti-LCAD antibody (Fig. 1C) . In lane 1, 15 ng of pure rat LCAD was directly applied to the gel as a standard. As can be seen in lanes 6 and 7, 133 and 13.3 ng of rat LCAD was completely removed by preabsorption with 2 pL anti-LCAD antibody, indicating the strong potency of this antibody. In contrast, no detectable amount of rat LCAD was removed by preabsorption with preimmune serum (lanes 3 and 4) or anti-MCAD antibody (lanes 4 and 5). These results demonstrate that the antibodies used in this study were indeed monospecific and potent.
In the second set of experiments, immunotitration of rat LCAD ( Fig. 2A) and MCAD (Fig. 2B) was carried out using a serially diluted crude rat liver mitochondrial extract as antigen. Preabsorption with 2 pL of anti-LCAD antibody removed most of the LCAD from the mitochondrial extract containing 50 and 25 pg protein, and all of the LCAD from the mitochondrial extract containing 12.5 pg protein ( Fig. 2A, row a) . However, preabsorption with anti-MCAD antibody did not reduce LCAD to any recognizable degree ( Fig. 2A, row b) . Preabsorption with 2 pL of anti-MCAD antibody similarly removed most of the MCAD proteins from mitochondrial extracts containing 25 pg protein and all of the MCAD from mitochondrial extracts containing 6.25 pg protein (Fig. 2B, row a) , but preabsorption with anti-LCAD antibody did not reduce the amount of MCAD (Fig.  2B, row b) . These results again demonstrated the high specificity and strong potency of the antibodies used in the present study.
In the third set of experiments, we tested the cross-reactivity of human MCAD with anti-LCAD antibody. The purified human MCAD preparation was probed with anti-MCAD (Fig. 3A) or anti-LCAD antibody (Fig. 3B ) with and without preabsorption with anti-MCAD antibody. The data shown in Figure 3A demonstrate that considerably more than 40 ng of MCAD could be precipitated with 2 pL of anti-MCAD antibody. No band could be detected with anti-LCAD antibody either with or without preabsorption with anti-MCAD antibody (Fig. 3B) . Similar experiments on human LCAD could not be carried out because it has not been purified.
Analysis of skin fibroblasts from patients with LCAD deficiency. First, immunoreactive LCAD and MCAD proteins in cultured skin fibroblasts from the three LCAD-deficient patients originally described by Hale et al. (1) were analyzed with and without preabsorption with anti-MCAD antibody (Fig. 4, A and  B) . For comparison, a normal (GM05756) and an MCADdeficient cell line (YH1475) were included in this experiment. When immunoblots were probed with anti-LCAD antibody, all three LCAD-deficient cells showed a clear single variant LCAD band that was indistinguishable in size from normal LCAD. The mobility of the LCAD band in the cell extract appeared slightly slower than that of pure rat LCAD on SDS-PAGE. The intensity of variant LCAD bands in the three LCAD-deficient cell lines was also similar to that in normal cells. When the same samples were analyzed for MCAD protein without preabsorption with anti-MCAD antibody, a normal MCAD band was detected in (B) . A, Pure human MCAD ( 1 33 and 13.3 ng) was detected using anti-MCAD antibody as a probe after preabsorption with preimmune rabbit serum (lanes 1 and 2 ) or anti-MCAD ( lanes  3 and 4 ) antibody. M, 133 and 13.3 ng of human MCAD were directly applied as standard. B, Pure human MCAD (133 and 13.3 ng) was probed with anti-LCAD antibody probe after preabsorption with preimmune rabbit serum (lanes 1 and 2 ) or anti-MCAD (lanes 3 and 4 ) antibody. M, 133 and 13.3 ng of human MCAD were directly applied as standard.
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. . . Fig. 4 . Immunoblot analysis of variant LCAD in skin fibroblasts from three patients with LCAD deficiency. A confluent culture of normal or mutant fibroblasts in two 150-cm2 flasks was harvested and treated with a detergent. The cell extract (300 pg protein in 100 pL) was preabsorbed with preimmune rabbit serum (odd-numbered lanes) or anti-MCAD antibody (even-numbered lanes). One third of each supernatant was subjected to the immunoblot analysis. A, LCAD detected using anti-LCAD antibody as a probe; B, MCAD detected using anti-MCAD antibody as a probe. At the left side of each panel, 100 and 10 ng of a purified rat enzyme are spotted. L, LCAD; M, MCAD. the normal and the three LCAD-deficient cell lines, but the MCAD band was detectable in none of them after preabsorption with anti-MCAD antibody. In the MCAD-deficient cells, no immunoreactive MCAD band was detectable even without preabsorption, indicating that YH1475 is negative for crossreactive materials. These data also provided evidence that LCAD and MCAD proteins were well distinguished in the present analytical system, despite the close sequence similarity (14-16; Indo Y, Glassberg R, Tanaka K, unpublished data).
Variant LCAD in six additional LCAD-deficient cell lines was further analyzed without preabsorption using anti-MCAD antibody as a probe (Fig. 5) . Again, a single variant LCAD band was detected in all six cell lines. The molecular size was indistinguishable from and the amount was comparable to that of LCAD in normal cells.
DISCUSSION
There has been a controversy concerning whether LCAD and MCAD are immunologically cross-reactive. Previously, Furuta et al. (17) observed that their purified rat LCAD and MCAD proteins each cross-reacted with antibody raised against the other. We have subsequently demonstrated using immunotitration and Ouchterlony double diffusion methods (6) that none of our purified preparations of rat acyl-CoA dehydrogenases, including LCAD and MCAD, cross-reacted with antibodies raised against the other acyl-CoA dehydrogenases (6) . The data presented here conclusively confirm that rat LCAD and MCAD are indeed immunologically distinct, not only in their native forms but also in their denatured forms. Thus, the cross-reactivity of rat LCAD and MCAD preparations with the respective antibodies observed by Furuta et al. (17) was due to cross-contamination of their preparations. Although human LCAD and MCAD are homologous, sharing 30.4% identical residues in their sequences (Indo Y, Yang-Feng T, Glassberg R, Tanaka K, unpublished data) , the present data suggest that they do not share common epitopes. This is probably because the stretches of consecutive identical amino acid residues shared by human LCAD and MCAD are short as in a pair of any two acyl-CoA dehydrogenases from the same species (17), usually extending only two to three residues, with the longest stretch being seven residues. In contrast, the stretches of consecutive identical amino acid residues shared by the same acyl-CoA dehydrogenase, including LCAD, from human and rat are generally much longer, often extending 15 to 17 residues. In the case of human and rat LCAD, the longest stretch was 42 residues (Indo Y, Yang-Feng T, Glassberg R, Tanaka K, unpublished data), rendering cross-reactivity to anti-rat LCAD antibody against human LCAD.
The characteristics of the variant LCAD protein studied here not only provide important insights into the nature of the biochemical basis of this disorder, but also contribute useful information for the molecular study of LCAD mutations. It was notable that the variant LCAD protein of normal size was detected in an amount comparable to normal in all nine unrelated LCAD-deficient cell lines regardless of their clinical phenotypes, suggesting that the LCAD mutation in these patients is likely to be a point mutation that produces a stable variant LCAD. This is in contrast to the findings with other acyl-CoA dehydrogenase deficiencies. In the study of 15 patients with isovaleric acidemia, at least five distinct types of variant isovaleryl-CoA dehydrogenase alleles were recognized with regard to the presence and absence of variant isovaleryl-CoA dehydrogenase proteins and their molecular size (18). In three known patients with SCAD deficiency, all variant SCAD were of normal size as tested with [35S]methionine-labeling, suggesting that they are point mutations (1 9) . However, the study of stability (9) and the sequence study (20) indicated that these SCAD mutations were extremely heterogenous. The pattern of variant MCAD is to some degree similar to that of variant LCAD. In the study of 13 MCAD-deficient cell lines, we previously showed using [35S] methionine-labeling and immunoprecipitation that all of them synthesized a normal-size variant MCAD (21), but when one of these cell lines (YH1475) was tested by immunoblot analysis in the present study, no variant MCAD band was detectable, as shown in Figure 4 . In the sequence study of nine independent MCAD-deficient cell lines including YH1475, a common point mutation, 985A+G transition, was detected in 17 variant alleles (22). In a subsequent study of 55 independent MCAD-deficient patients, we found that the prevalence of 985A+G was 89.1 % of variant MCAD alleles (Yokota I, Coats PM, Hale DE, Rinaldo P, Tanaka K, unpublished results). Absence of cross-reactive variant MCAD in 985A+G homozygous cells have been confirmed in a much larger number of cell lines (Coates PM, Indo Y, Young D, Hale DE, Tanaka K, unpublished results).
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